CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 8 No. 4
 

Modeling Cancer Risks ‘Problematic But Still Useful’

April 1, 1999

ANAHEIM, Calif—“Mathematical modeling of cancer risk involves a number of unknown or inadequately understood relationships and factors, but still can provide worthwhile hypotheses for further testing,” Troyce Jones, MS, senior research scientist, Oak Ridge National Laboratory, said at a symposium on environmental hazards and cancer at the annual meeting of the American Association for the Advancement of Science (AAAS).

Mr. Jones, a mathematician, said that “we do not know enough about carcinogenic processes to derive from first principles the risk relationships between exposure to hazards and development of disease.”

‘It Takes a Large Dose’

On a molecular or cellular level, he said, “it takes a large dose of a hazardous substance to cause cancer, in the neighborhood of thousands of molecules per cell. Studies of the carcinogenic properties of aflatoxin, for example, suggest that a thousand molecules per cell per day are needed.”

Cancers usually develop from a single cell, Mr. Jones said, but they generally are not diagnosed until that single cell has divided and multiplied to reach a volume of a gram, or a billion cells. “Modeling risk, however, involves going backwards to discern doses of one of many agents involved in the carcinogenic process,” he said.

Further complicating any calculation is the fact that the immune system is always a mediator, although it is very difficult to model because of the many complex relationships among its elements. “The chemicals that drive the immune system, and their relationships are still not known, and humans have some two dozen cytokines,” he said. “All these different cells and cytokines interact with each other.”

Risk analysis, furthermore, traditionally depends on the assumption that “a human is a human,” Mr. Jones said. “For a great variety of reasons, known and unknown, however, the immune system of any individual varies from day to day, from season to season; it varies with almost everything.”

What is the Connection?

In an ideal world, Mr. Jones commented, one would want to know the connections between chemical exposures and development of disease. “But in spite of all the knowledge presented at this meeting and found in the published literature,” he said, “science still cannot get from one to the other.”

Despite these serious issues, however, some factors are very strongly correlated with cancer cell proliferation, such as unrepaired DNA double strand breaks. “The prevailing theory that oxygen radicals relate to risk, for example, gets stronger every year instead of weaker,” he said. “The same is true for the inverse correlation between cancer and factors that strengthen immunity.”

He pointed out that 81% of studies show a twofold protection from cancer from high consumption of fruits and vegetables, rich in antioxidants.

Useful in Suggesting Hypotheses

“Although, at present, knowledge is insufficient for modeling to serve a predictive function for many cancers, it nonetheless is very useful in exposing relationships that suggest hypotheses for further testing,” he concluded.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Soluble HER2 Levels Prognostic Factor in HER2+ Breast Cancer
  • ASCO: PD-L1 Antibody Elicits Durable Response in RCC
  • RECORD-3: Sunitinib Still Standard First-Line Treatment in Metastatic RCC
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy